Consistent with previous findings in EGFR mutant NSCLC, we found HGF suppressed sensitivity to gefitinib via the MET pathway without association to ErbB3 in wild-type EGFR NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.